%0 Journal Article
%T Remifentanil Negatively Regulates RANKL-Induced Osteoclast Differentiation and Bone Resorption by Inhibiting c-Fos/NFATc1 Expression
%A Chul-Woo Baek
%A Eun-Jung Kim
%A Gyeong-Jo Byeon
%A Hyung-Joon Kim
%A Ji-Uk Yoon
%A Ji-Young Yoon
%J Archive of "Tissue Engineering and Regenerative Medicine".
%D 2018
%R 10.1007/s13770-018-0116-z
%X Effect of remifentanil treatment on cell viability and proliferation. Remifentanil did not affect cell proliferation and did not have cytotoxic effects on osteoclast precursor cells. A BMMs were cultured in a medium containing the indicated concentrations of remifentanil (0¨C100 ng/ml) for 24 h. Cell viability was evaluated by an MTT assay. B BMMs were cultured in osteoclastogenic medium for 3 days together with remifentanil (0¨C100 ng/ml). Cell proliferation was measured by MTT assay. BMMs bone marrow-derived macrophage
%K Remifentanil
%K Osteoclast
%K Bone resorption
%K RANKL
%K ERK
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171682/